VB
Vesalius Biocapital Partners
Venture CapitalActiveVesalius Biocapital Partners invests in companies active in human health through venture capital funds raised since 2007.
36
Investments
6
Exits
$350M
AUM
16.7%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Vesalius Biocapital Partners.
Investment Thesis & Strategy
Vesalius Biocapital Partners invests in various stages of biotech and fintech companies focused on human health, leveraging its venture capital funds established since 2007.
Investment Activity
Deals per year over the last 14 years
3
20081
20092
20101
20110
20120
20130
20141
20151
20162
20170
20180
20190
20201
2021Portfolio Companies
Selected investments from their portfolio of 36 companies
E
Endogena Therapeutics
Biotech · Series A, 2021
i
iTeos Therapeutics
Biotech · Series A, 2017
H
Horama
Biotech · Series A, 2017
N
Novadip Biosciences
Biotech · Series A, 2016
P
Promethera Biosciences
Biotech · Series B, 2015
B
Biocartis
Biotech · Growth, 2011
C
Celyad
Biotech · Growth, 2010
C
Cardio3 BioSciences
Biotech · Growth, 2010
B
Bone Therapeutics
Biotech · Growth, 2009
M
MDxHealth
Biotech · Growth, 2008
I
Innate Pharma
Biotech · Growth, 2008
A
Ablynx
Biotech · Growth, 2008
Notable Exits
CompanyTypeYearValue / Acquirer
iTeos TherapeuticsIPO2021—
ObsEvaIPO2017—
GenSight BiologicsIPO2016—
CelyadIPO2015—
Bone TherapeuticsIPO2015—
Innate PharmaIPO2006—
Frequently Asked Questions
Vesalius Biocapital Partners focuses on Series A, Series B, Series C+ stage investments.
Related Investors
CRP Sante
Strassen, Luxembourg · 1 deals
Bessemer Venture Partners
Redwood City, United States · 971 deals
Threshold
Menlo Park, United States · 841 deals
Lightspeed Venture Partners
Menlo Park, United States · 839 deals
Index Ventures
San Francisco, United States · 827 deals
Andreessen Horowitz
Menlo Park, United States · 826 deals